Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Prostatic Neoplasms 2Ovarian Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Solid Tumor 1Peripheral Nervous System Diseases 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Head and Neck Neoplasms 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Imatinib Mesylate 86nilotinib 59fludarabine phosphate 46Cyclophosphamide 45Mycophenolic Acid 37Whole-Body Irradiation 35Dasatinib 32fludarabine 31Tacrolimus 29Cyclosporine 24Busulfan 23Peripheral Blood Stem Cell Transplantation 22Methotrexate 20bosutinib 18Cytarabine 18Granulocyte Colony-Stimulating Factor 16Filgrastim 16Melphalan 14thymoglobulin 13Antilymphocyte Serum 13Stem Cell Transplantation 12sargramostim 11Thiotepa 11Interferon-alpha 10Cord Blood Stem Cell Transplantation 9asciminib 8Cyclosporins 8ponatinib 7Sirolimus 7Radiotherapy 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × BID protein, human × Clear all
NCT04948333 2026-03-18

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

Novartis

Phase 3 Completed
199 enrolled 13 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡